ArticleBMC cancer2018
Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Mechanisms of Action and Biomarker Potential of ncRNAs in Hepatocellular Carcinoma and Liver Fibrosis: A Review.Analytical cellular pathology (Amsterdam) · 2026Review
- Ontologies and Knowledge Graphs in Oncology Research.Cancers · 2022Review
- Effects of Tumor-Derived DNA on CXCL12-CXCR4 and CCL21-CCR7 Axes of Hepatocellular Carcinoma Cells and the Regulation of Sinomenine Hydrochloride.Frontiers in oncology · 2022Article
- Serum exosomal miR-34a as a potential biomarker for the diagnosis and prognostic of hepatocellular carcinoma.Journal of Cancer · 2022Article
- Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis.Bioengineered · 2021Article
- The comprehensive landscape of miR-34a in cancer research.Cancer metastasis reviews · 2021Review
- miR-939-3p promotes epithelial-mesenchymal transition and may be used as a prognostic marker in hepatocellular carcinoma.Oncology letters · 2020Article
- A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer.OncoTargets and therapy · 2020Review
- Polo like kinase 1 expression in cervical cancer tissues generated from multiple detection methods.PeerJ · 2020Article
- MicroRNA-197-3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma.Oncology letters · 2019Article
- Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma.OncoTargets and therapy · 2019Article
- Dysregulated MicroRNA Fingerprints and Methylation Patterns in Hepatocellular Carcinoma, Cancer Stem Cells, and Mesenchymal Stem Cells.Frontiers in cell and developmental biology · 2019Review
- Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.Frontiers in pharmacology · 2019Review
- MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulatingCancer management and research · 2019Article
- Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma.Thoracic cancer · 2018Article
- miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma.BioMed research international · 2018Article
- The emergence of long non-coding RNAs in hepatocellular carcinoma: an update.Journal of Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCurrently, some studies have demonstrated that miR-34a could serve as a suppressor of several cancers including hepatocellular carcinoma (HCC). Previously, we discovered that miR-34a was downregulated in HCC and involved in the tumorigenesis and progression of HCC; however, the mechanism remains unclear. The purpose of this study was to estimate the expression of miR-34a in HCC by applying the microarray profiles and analyzing the predicted targets of miR-34a and their related biological pathways of HCC.
methodsGene expression omnibus (GEO) datasets were conducted to identify the difference of miR-34a expression between HCC and corresponding normal tissues and to explore its relationship with HCC clinicopathologic features. The natural language processing (NLP), gene ontology (GO), pathway and network analyses were performed to analyze the genes associated with the carcinogenesis and progression of HCC and the targets of miR-34a predicted in silico. In addition, the integrative analysis was performed to explore the targets of miR-34a which were also relevant to HCC.
resultsThe analysis of GEO datasets demonstrated that miR-34a was downregulated in HCC tissues, and no heterogeneity was observed (Std. Mean Difference(SMD) = 0.63, 95% confidence intervals(95%CI):[0.38, 0.88], P < 0.00001; P
conclusionOur results may lead researchers to understand the molecular mechanism of miR-34a in the diagnosis, prognosis and therapy of HCC. Therefore, the interaction between miR-34a and its targets may promise better prediction and treatment for HCC. And the experiments in vivo and vitro will be conducted by our group to identify the specific mechanism of miR-34a in the progress and deterioration of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.